Your Wearable Reads Electrodermal Activity for Stress. Can the Same Signal Be Used to Treat Pain?
The site's existing EDA coverage is about how accurately a wearable reads your stress. This trial tested something else entirely: training against the same signal to treat chronic pain.
This piece covers one large multicenter controlled clinical trial testing a dedicated electrodermal biofeedback device for reducing chronic pain and inflammation. It does not cover consumer wearable stress-score accuracy, and it is not medical advice for managing chronic pain.
A multicenter controlled clinical trial with 1,015 treatment participants and 950 placebo controls found that active electrodermal biofeedback significantly reduced self-reported chronic pain compared to placebo (p<0.05), using a dedicated clinical biofeedback device, not a consumer wearable. This is a functionally different use of electrodermal activity than the passive stress-score readout most wearables provide: the trial tested actively training against the signal as therapy, not simply reading it to report a stress level.
Two different things you can do with the same signal
The existing coverage on this cluster is about how accurately a wearable's electrodermal activity sensor reads stress passively, as a number you check. A large multicenter clinical trial tested something structurally different: using the same underlying signal, electrodermal activity, as the basis for active biofeedback therapy aimed at reducing chronic pain.
The distinction matters. Reading a passive EDA number and training against that same signal in structured biofeedback sessions are two different uses of the same physiological measurement, and evidence for one doesn't automatically transfer to the other.
1 study
- In a multicenter trial across 20 general practice medical centers, 1,015 patients (401 men, 614 women, aged 30-86) with chronic pain and other medically unexplained symptoms received electrodermal biofeedback via a dedicated device (RegMatEx, BioTekna), while 950 patients received placebo biofeedback. All patients received six 30-minute sessions, twice weekly over three weeks. Perceived pain, measured on the Numeric Rating Scale, was significantly reduced in the treatment group compared to placebo (p<0.05). Systemic inflammation was assessed via morning C-reactive protein.
The device tested is not a consumer wearable
The device used in this trial, RegMatEx, is a dedicated clinical electrodermal biofeedback device administered in a general practice setting over structured, supervised sessions, not a consumer smartwatch or fitness ring worn continuously throughout the day. The trial doesn't test, and doesn't claim to test, whether wearing a Whoop, Fitbit, or Garmin and passively checking its stress score does anything for chronic pain.
What it does establish is that the underlying physiological signal, electrodermal activity, is being used in real, published clinical research for something beyond stress measurement: as the basis for a structured, active-training intervention with a measured clinical outcome (pain, via the Numeric Rating Scale) rather than just a number on a screen.
This trial data was collected in 2010-2011 and published in 2020, using a specific clinical device (RegMatEx). It is not a study of any consumer wearable brand's stress-score feature, and its findings shouldn't be read as evidence about what those consumer features do.
Where the evidence stops
The portion of the trial's findings summarized here does not include the specific inflammation (CRP) results or the magnitude of pain reduction beyond "statistically significant," so those specifics aren't claimed here. The trial also studied patients with diagnosed chronic pain and medically unexplained symptoms specifically, not a general healthy population using a wearable for everyday stress tracking.
Read this as evidence that electrodermal activity has a documented, structurally different clinical application beyond passive stress reading, not as a claim that any current consumer wearable feature has been validated for pain treatment.
No consumer wearable brand or feature is tested, named, or implied by this trial. The connection here is limited to the shared underlying physiological signal (electrodermal activity), not any product claim.
Common questions
Can electrodermal biofeedback actually reduce chronic pain?
In a multicenter controlled trial of 1,015 treatment patients versus 950 placebo controls, active electrodermal biofeedback significantly reduced self-reported pain on the Numeric Rating Scale compared to placebo (p<0.05).
Is this the same as my wearable's stress score?
No. The trial used a dedicated clinical biofeedback device (RegMatEx) in structured, supervised sessions, actively training against the electrodermal signal, not a consumer wearable passively reading and reporting a stress number.
How many people were in this study?
1,015 patients received the active electrodermal biofeedback treatment across 20 general practice centers, compared against 950 patients who received placebo biofeedback.
Does this mean wearable stress scores can treat pain?
No. The trial doesn't test any consumer wearable's stress-score feature. It shows that actively training against the electrodermal signal, in a structured clinical setting, is a different and separately studied use of the same underlying signal.